Skip to main content
< Back to news
Imagen: Esteve

Esteve’s R&D&I has once again received the qualification ”Excellent” in the Profarma program

Once again, Esteve's research activity has received the qualification ''Excellent'' in the 2018 call of the Profarma program, resolved by the Spanish Ministry of Industry, Commerce and Tourism.The pharmaceutical group – that in 2012 established its key units for the discovery of drugs and preclinical development in the Barcelona Science Park– has been recognized with the highest rating for its commitment to innovation and quality of its research.


The rating of “Excellent” and in Group A of the ‘Profarma program recognizes Esteve as a company with significant and cutting-edge innovative research activity in Spain. 

 In 2017, Esteve invested 81 million Euros in R&D&I activities, with a substantial part of its workforce dedicated to the discovery and development of new drugs, and with several highly innovative programs of their own in New Molecular Entities, which are currently in different research phases, mainly in the field of neuroscience. 

Esteve has its own R&D center. Since 2012, all the key units for drug discovery and preclinical development are located in the Barcelona science Park, the scientific park of the University of Barcelona, at facilities of 2,400 m2.

The primary aim of the Profarma (2017-2020) program  is to increase the competitiveness of the pharmaceutical industry in Spain, promoting the modernization of the sector and furthering those activities that prove to be essential and provide greater added value, such as investment in new industrial plants and new technologies for production, and fostering research, development and innovation.

In the 2018 call, this program has evaluated a total of 54 applications from pharmaceutical companies, of which 37 have been described as ‘Excellent’, ‘Very good’, ‘Good’ and ‘Acceptable’.